Advanced search
Publication Cover
Expert Review of Hematology Volume 7, 2014 - Issue 2
Submit an article Journal homepage
90
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

Amer M ZeidanDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USACorrespondence[email protected]
,
Thomas PrebetDépartement d'hématologie, Aix-Marseille University, Marseille, France
,
Ehab Saad AldinDepartment of Internal Medicine, Medstar Good Samaritan Hospital, Baltimore, MD, USA
&
Steven David GoreDepartment of Medicine, Yale University, New Haven, CT, USA
Pages 191-194 | Published online: 24 Feb 2014

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Amer M. Zeidan, Maximilian Stahl & Rami Komrokji. (2016) Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs 21:3, pages 283-300.
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now

Articles from other publishers (3)

F J Campos-Laborie, A Risueño, M Ortiz-Estévez, B Rosón-Burgo, C Droste, C Fontanillo, R Loos, J M Sánchez-Santos, M W Trotter & J De Las Rivas. (2019) DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling. Bioinformatics 35:19, pages 3651-3662.
Crossref
Aziz NazhaMikkael A. SekeresSteven D. Gore & Amer M. Zeidan. (2015) Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. The Oncologist 20:9, pages 1069-1076.
Crossref
Amer M. Zeidan, Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Rhett P. Katterling, Martin S. Tallman & Steven D. Gore. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal of Haematology 167:1, pages 62-68.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.